ANI Pharmaceuticals (NASDAQ: ANIP) exec sells 500 shares via plan

Rhea-AI Filing Summary

ANI Pharmaceuticals executive Meredith W. Cook, Senior Vice President, General Counsel and Secretary, reported a small open-market sale of company common stock. On January 13, 2026, she sold 500 shares of ANI Pharmaceuticals common stock at a price of $84.33 per share, as disclosed in a Form 4 insider trading report.

After this transaction, Cook directly beneficially owned 74,374 shares of ANI Pharmaceuticals common stock. The filing notes that this sale was carried out under a pre-established Rule 10b5-1 trading plan that she adopted on September 15, 2025, indicating the trades were scheduled in advance rather than timed at her discretion.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Meredith

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SR. VP, GENERAL COUNSEL & SEC.

3. Date of Earliest Transaction (Month/Day/Year)
01/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/13/2026		S(1)		500	D	$84.33	74,374	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

Remarks:

	/s/ Meredith W. Cook	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Meredith W. Cook?

ANI Pharmaceuticals reported that Meredith W. Cook, Senior Vice President, General Counsel and Secretary, sold 500 shares of the company’s common stock in an open-market transaction on January 13, 2026.

At what price were the ANI Pharmaceuticals (ANIP) shares sold in this Form 4?

The reported sale of ANI Pharmaceuticals common stock was executed at a price of $84.33 per share on January 13, 2026.

How many ANI Pharmaceuticals (ANIP) shares does Meredith W. Cook own after the transaction?

Following the reported sale, Meredith W. Cook directly beneficially owned 74,374 shares of ANI Pharmaceuticals common stock.

Was the ANI Pharmaceuticals (ANIP) insider sale under a Rule 10b5-1 plan?

Yes. The filing states that the sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Meredith W. Cook on September 15, 2025.

What is Meredith W. Cook’s role at ANI Pharmaceuticals (ANIP)?

According to the filing, Meredith W. Cook serves as Senior Vice President, General Counsel & Secretary of ANI Pharmaceuticals.

Is the reported ANI Pharmaceuticals (ANIP) insider transaction held directly or indirectly?

The Form 4 indicates that the 500 shares sold and the remaining 74,374 shares are held with direct ownership by Meredith W. Cook.